Published in Nat Med on January 06, 2013
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med (2014) 6.06
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med (2015) 2.53
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 2.53
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A (2014) 2.50
An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell (2013) 2.30
Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol (2014) 1.95
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood (2014) 1.94
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med (2015) 1.88
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis (2015) 1.77
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood (2013) 1.72
Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol (2013) 1.68
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol (2014) 1.65
Many players in BCL-2 family affairs. Trends Biochem Sci (2014) 1.64
Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ (2013) 1.54
Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood (2014) 1.53
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet (2015) 1.52
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med (2015) 1.51
Axon Degeneration Gated by Retrograde Activation of Somatic Pro-apoptotic Signaling. Cell (2016) 1.49
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis (2015) 1.44
Mitochondria: gatekeepers of response to chemotherapy. Trends Cell Biol (2013) 1.44
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer (2016) 1.42
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia (2013) 1.39
The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ (2015) 1.38
Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer (2013) 1.36
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther (2014) 1.35
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev (2014) 1.30
Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci (2013) 1.29
ABT-199: taking dead aim at BCL-2. Cancer Cell (2013) 1.24
Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther (2014) 1.23
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. ACS Med Chem Lett (2014) 1.23
Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun (2016) 1.23
Evading apoptosis in cancer. Trends Cell Biol (2013) 1.17
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A (2014) 1.17
Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ (2013) 1.16
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia (2014) 1.16
An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat Cell Biol (2015) 1.16
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res (2014) 1.15
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov (2015) 1.15
Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem Biol (2013) 1.15
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol (2015) 1.14
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov (2014) 1.14
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell (2015) 1.13
Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer (2015) 1.13
Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol (2014) 1.13
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res (2015) 1.12
Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism. Mol Cell (2015) 1.12
Role of miR-15/16 in CLL. Cell Death Differ (2014) 1.12
Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol (2014) 1.07
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell (2016) 1.06
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta (2015) 1.05
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med (2015) 1.04
Genomic landscape of liposarcoma. Oncotarget (2015) 1.04
Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol (2015) 1.03
Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ (2014) 1.03
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia (2014) 1.02
Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet (2013) 1.02
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood (2014) 1.01
Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget (2015) 1.00
New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget (2015) 1.00
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica (2014) 1.00
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica (2014) 1.00
Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. Bioorg Med Chem (2013) 1.00
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia (2014) 0.98
Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood (2015) 0.97
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood (2014) 0.97
Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab (2014) 0.97
3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation. J Med Chem (2014) 0.96
Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance. Oncogene (2014) 0.96
Structure-guided rational design of α/β-peptide foldamers with high affinity for BCL-2 family prosurvival proteins. Chembiochem (2013) 0.96
Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis. Nat Microbiol (2016) 0.96
Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax. Cell Death Dis (2015) 0.95
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia (2015) 0.95
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. Oncotarget (2015) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res (2013) 0.94
A time to kill: targeting apoptosis in cancer. Int J Mol Sci (2015) 0.94
Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Oncotarget (2014) 0.94
Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget (2015) 0.93
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Nat Rev Drug Discov (2016) 0.93
Apoptotic machinery diversity in multiple myeloma molecular subtypes. Front Immunol (2013) 0.93
In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget (2014) 0.93
Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ (2015) 0.93
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma (2015) 0.93
Mitochondria-Judges and Executioners of Cell Death Sentences. Mol Cell (2016) 0.93
Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov (2016) 0.92
Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. Oncotarget (2015) 0.92
Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs (2013) 0.92
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood (2013) 0.92
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia (2015) 0.92
An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid (2013) 0.91
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep (2013) 0.91
Apoptosis therapy: driving cancers down the road to ruin. Nat Med (2013) 0.91
Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin Cancer Res (2014) 0.91
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. Cancer Res (2015) 0.91
BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One (2014) 0.91
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2013) 0.91
Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia (2013) 0.90
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J (2015) 0.90
The hallmarks of cancer. Cell (2000) 113.05
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (1988) 14.66
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell (1993) 14.39
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science (1997) 9.73
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature (1996) 8.37
Involvement of the bcl-2 gene in human follicular lymphoma. Science (1985) 8.19
Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell (1986) 7.34
Programmed anuclear cell death delimits platelet life span. Cell (2007) 5.98
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Bcl-2 family proteins are essential for platelet survival. Cell Death Differ (2007) 2.67
Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci U S A (2001) 2.60
An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res (2000) 2.47
Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A (2004) 2.36
Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ (2007) 2.12
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood (2007) 2.12
Expression of bcl-xL can confer a multidrug resistance phenotype. Blood (1995) 2.11
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res (2008) 2.10
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem (2007) 2.09
Structural plasticity in a remodeled protein-protein interface. Science (1997) 2.05
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol (2006) 2.02
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem (2008) 1.85
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia (2009) 1.63
The management of tumor lysis syndrome. Nat Clin Pract Oncol (2006) 1.60
Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol (2006) 1.39
Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal Biochem (2002) 1.38
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther (2011) 1.36
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem (2006) 1.33
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood (1996) 1.24
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood (2006) 1.23
Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia (2010) 1.22
Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol (2012) 1.12
VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther (2010) 1.08
Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction. Expert Opin Drug Discov (2008) 1.05
New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr Opin Hematol (2011) 1.01
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. Am J Clin Pathol (2000) 0.96
mRNA display selection of a high-affinity, Bcl-X(L)-specific binding peptide. FASEB J (2010) 0.96
Assays to measure p53-dependent and -independent apoptosis. Methods Mol Biol (2009) 0.94
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell (2005) 13.59
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev (2005) 8.95
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene (2003) 7.41
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Programmed anuclear cell death delimits platelet life span. Cell (2007) 5.98
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell (2008) 5.37
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol (2011) 5.05
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol (2003) 4.90
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Systematic identification of C. elegans miRISC proteins, miRNAs, and mRNA targets by their interactions with GW182 proteins AIN-1 and AIN-2. Mol Cell (2007) 4.22
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99
Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell (2002) 3.86
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science (2003) 3.59
T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol (2002) 3.57
c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem (2008) 3.54
A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev (2006) 3.49
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
Proinflammatory cytokine expression profile in degenerated and herniated human intervertebral disc tissues. Arthritis Rheum (2010) 3.45
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A (2007) 3.41
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol (2011) 3.33
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood (2013) 3.23
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res (2010) 3.20
Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature (2002) 3.15
Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol (2009) 3.14
The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell (2007) 3.13
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med (2007) 3.09
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell (2005) 3.04
XIAP discriminates between type I and type II FAS-induced apoptosis. Nature (2009) 3.00
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol (2004) 2.90
Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke (2012) 2.88
Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell (2013) 2.75
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov (2013) 2.74
Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes. BMC Bioinformatics (2004) 2.73
Functional materials for rechargeable batteries. Adv Mater (2011) 2.71
Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature (2006) 2.69
Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLoS One (2010) 2.60
Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J (2007) 2.59
K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell (2010) 2.52
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell (2011) 2.51
Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol (2013) 2.51
A cluster of interferon-γ-inducible p65 GTPases plays a critical role in host defense against Toxoplasma gondii. Immunity (2012) 2.50
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther (2011) 2.48
Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation (2008) 2.48
Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell (2007) 2.46
Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem (2001) 2.45